Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN-γ Measurements.

MLA

Ita, Michael I., et al. “Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma CfDNA, LDH, VEGF, PD-L1, and IFN-γ Measurements.” Anticancer Research, vol. 42, no. 2, Feb. 2022, pp. 801–10. EBSCOhost, https://doi.org/10.21873/anticanres.15538.

APA

Ita, M. I., Wang, J. H., Heffron, C. C., Power, D. G., Nolan, Y., Toulouse, A., Lim, C. C. H., Fanning, N., & Redmond, H. P. (2022). Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN-γ Measurements. Anticancer Research, 42(2), 801–810. https://doi.org/10.21873/anticanres.15538

Chicago

Ita, Michael I, Jiang H Wang, Cynthia C Heffron, Derek G Power, Yvonne Nolan, André Toulouse, Chris C H Lim, Noel Fanning, and Henry P Redmond. 2022. “Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma CfDNA, LDH, VEGF, PD-L1, and IFN-γ Measurements.” Anticancer Research 42 (2): 801–10. doi:10.21873/anticanres.15538.